Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Study of CUR-N399 in Healthy Volunteers
NCT05016687Phase 1Completed
- Sponsor
- Curovir AB
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CUR-N399 in chronic obstructive pulmonary disease (COPD), enterovirus infection and rhinovirus infection (6 arms), sponsored by Curovir AB. Primary endpoints: Adverse events (AE), Clinically significant changes in electrocardiograms and 6 more. Started Jul 2021; status: completed.
02
Drugs
CUR-N399
03
Conditions
chronic obstructive pulmonary disease (COPD)enterovirus infectionrhinovirus infection
Beyond the preview
Go deeper on NCT05016687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016687.